1739 related articles for article (PubMed ID: 8439988)
1. Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3.
Ohta S; Honda A; Tokutake Y; Yoshida H; Hanai N
Cancer Immunol Immunother; 1993; 36(4):260-6. PubMed ID: 8439988
[TBL] [Abstract][Full Text] [Related]
2. A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities.
Shitara K; Kuwana Y; Nakamura K; Tokutake Y; Ohta S; Miyaji H; Hasegawa M; Hanai N
Cancer Immunol Immunother; 1993 Jun; 36(6):373-80. PubMed ID: 8500110
[TBL] [Abstract][Full Text] [Related]
3. Recombinant antibodies against ganglioside expressed on tumor cells.
Hanai N; Nakamura K; Shitara K
Cancer Chemother Pharmacol; 2000; 46 Suppl():S13-7. PubMed ID: 10950141
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of chimeric anti-(ganglioside GD3) antibody KM871: antitumor activity in xenograft model of melanoma and effector function analysis.
Kanazawa J; Ohta S; Shitara K; Fujita F; Fujita M; Hanai N; Akinaga S; Okabe M
Cancer Immunol Immunother; 2000 Jul; 49(4-5):253-8. PubMed ID: 10941908
[TBL] [Abstract][Full Text] [Related]
5. Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells.
Welt S; Carswell EA; Vogel CW; Oettgen HF; Old LJ
Clin Immunol Immunopathol; 1987 Nov; 45(2):214-29. PubMed ID: 3665201
[TBL] [Abstract][Full Text] [Related]
6. Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody.
Chapman PB; Gillies SD; Houghton AN; Reilly RM
Cancer Immunol Immunother; 1994 Sep; 39(3):198-204. PubMed ID: 7522964
[TBL] [Abstract][Full Text] [Related]
7. The idiotype (Id) cascade in mice elicited the production of anti-R24 Id and anti-anti-Id monoclonal antibodies with antitumor and protective activity against human melanoma.
Ramos AS; Parise CB; Travassos LR; Han SW; de Campos-Lima PO; de Moraes JZ
Cancer Sci; 2011 Jan; 102(1):64-70. PubMed ID: 21070480
[TBL] [Abstract][Full Text] [Related]
8. Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis.
Cheresh DA; Honsik CJ; Staffileno LK; Jung G; Reisfeld RA
Proc Natl Acad Sci U S A; 1985 Aug; 82(15):5155-9. PubMed ID: 3860849
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity.
Thurin J; Thurin M; Kimoto Y; Herlyn M; Lubeck MD; Elder DE; Smereczynska M; Karlsson KA; Clark WM; Steplewski Z
Cancer Res; 1987 Mar; 47(5):1229-33. PubMed ID: 3815333
[TBL] [Abstract][Full Text] [Related]
10. Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity.
Chapman PB; Lonberg M; Houghton AN
Cancer Res; 1990 Mar; 50(5):1503-9. PubMed ID: 2105840
[TBL] [Abstract][Full Text] [Related]
11. Increased tumor cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides.
Zhang S; Helling F; Lloyd KO; Livingston PO
Cancer Immunol Immunother; 1995 Feb; 40(2):88-94. PubMed ID: 7882387
[TBL] [Abstract][Full Text] [Related]
12. Immunorecognition of ganglioside epitopes: correlation between affinity and cytotoxicity of ganglioside antibodies.
Dippold W; Bernhard H
Eur J Cancer; 1992; 28A(10):1605-10. PubMed ID: 1382491
[TBL] [Abstract][Full Text] [Related]
13. An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy.
Ravindranath MH; Morton DL; Irie RF
Cancer Res; 1989 Jul; 49(14):3891-7. PubMed ID: 2472199
[TBL] [Abstract][Full Text] [Related]
14. Human monoclonal antibody to ganglioside GD2-inhibited human melanoma xenograft.
Katano M; Jien M; Irie RF
Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1053-9. PubMed ID: 6540688
[TBL] [Abstract][Full Text] [Related]
15. Human melanoma cell lines deficient in GD3 ganglioside expression exhibit altered growth and tumorigenic characteristics.
Nakano J; Raj BK; Asagami C; Lloyd KO
J Invest Dermatol; 1996 Oct; 107(4):543-8. PubMed ID: 8823358
[TBL] [Abstract][Full Text] [Related]
16. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
[TBL] [Abstract][Full Text] [Related]
17. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin.
Honsik CJ; Jung G; Reisfeld RA
Proc Natl Acad Sci U S A; 1986 Oct; 83(20):7893-7. PubMed ID: 3094017
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro.
Kawashima I; Tada N; Fujimori T; Tai T
J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo antitumor effects of murine monoclonal antibody NCC-ST-421 reacting with dimeric Le(a) (Le(a)/Le(a)) epitope.
Watanabe M; Ohishi T; Kuzuoka M; Nudelman ED; Stroud MR; Kubota T; Kodairo S; Abe O; Hirohashi S; Shimosato Y
Cancer Res; 1991 Apr; 51(8):2199-204. PubMed ID: 1706961
[TBL] [Abstract][Full Text] [Related]
20. Homophilic binding of mouse monoclonal antibodies against GD3 ganglioside.
Chapman PB; Yuasa H; Houghton AN
J Immunol; 1990 Aug; 145(3):891-8. PubMed ID: 1695649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]